Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome
a study on Polycystic Ovary Syndrome
Summary
- Eligibility
- for females ages 18-35 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- AbbVie
- Links
- This clinical study may be evaluating a usage that is not currently FDA approved. Please see US Prescribing Information for approved uses.
- ID
- NCT03951077
- Phase
- Phase 2
- Study Type
- Interventional
- Last Updated